This is a working overview of GHRH, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-05. Anything still debated is marked as such rather than presented as settled.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
While the Treaties and Regulations will have direct effect (if clear, unconditional and immediate), Directives do not generally give citizens (as opposed to the member state) standing to sue other citizens. In theory, this is because TFEU article 288 says Directives are addressed to the member states and usually "leave to the national authorities the choice of form and methods" to implement. In part this reflects that directives often create minimum standards, leaving member states to apply higher standards. For example, the Working Time Directive requires that every worker has at least 4 weeks paid holidays each year, but most member states require more than 28 days in national law. However, on the current position adopted by the Court of Justice, citizens have standing to make claims based on national laws that implement Directives, but not from Directives themselves. Directives do not have so called "horizontal" direct effect (i.e. between non-state parties). This view was instantly controversial, and in the early 1990s three Advocate Generals persuasively argued that Directives should create rights and duties for all citizens. The Court of Justice refused, but there are five large exceptions. First, if a Directive's deadline for implementation is not met, the member state cannot enforce conflicting laws, and a citizen may rely on the Directive in such an action (so called "vertical" direct effect).
=== Healthcare === On 11 January, Lula signed into law the "National Policy for the Prevention of Self-Mutilation and Suicide", created by the Health Ministry with the objective of giving mental health support for public security agents. On 20 January, Lula signed a bill, classifying community and disease control agents as health professionals. Also on 20 January, under pressure from religious entities, Lula created the "Department of Support for Therapeutic Communities", aimed at treating drug addicts; after the measure was criticized by human rights organizations, the Ministry of Social Development and Fight against Hunger announced that it would review the decision. The Brazilian Association of Mental Health had also spoken out against the measure in a repudiation note. On 8 March, International Women's Day, Lula announced the creation of the "Programme for the Protection and Promotion of Menstrual Dignity", which provides distribution of menstrual pads by the Sistema Único de Saúde (SUS) to people in vulnerable situations, below the Poverty threshold. The document regulates the Law nº 14.214/2021, which had been vetoed by Jair Bolsonaro in 2021. 8 million people will benefit from the initiative, according to specialists, with an investment of 418 million reals per year, according to the Ministry of Health.
carbamylation the addition of Isocyanic acid to a protein's N-terminus or the side-chain of Lys. carbonylation the addition of carbon monoxide to other organic/inorganic compounds. glycation, the addition of a sugar molecule to a protein without the controlling action of an enzyme. glutarylation, the addition of a glutaryl group to lysine residues malonylation, the addition of a malonyl group to lysine residues methylmalonylation, the addition of a methylmalonyl group to lysine residues spontaneous isopeptide bond formation, between lysine and aspartic acid or asparagine, as found in many surface proteins of Gram-positive bacteria. succinylation, addition of a succinyl group to lysine
== Treatments == Prophylaxis and treatment with an anti-inflammatory agent may stop progression of the reaction. Oral aspirin or ibuprofen every four hours for a day or 60 mg of prednisone orally or intravenously has been used as an adjunctive treatment . However, steroids are generally of no benefit. Patients must be closely monitored for the potential complications (collapse and shock) and may require IV fluids to maintain adequate blood pressure. If available, meptazinol, an opioid analgesic of the mixed agonist/antagonist type, should be administered to reduce the severity of the reaction. Anti TNF-α may also be effective.
He wrote in McClure's in 1908 that the claims were based on self-diagnosis or secondhand reports from doctors, and attributed them to the placebo effect. In 1900 medical lecturer William Purrington called the beneficiaries "hysterical patients ... the victims of obscure nervous ailments." Rodney Stark writes that a key to Christian Science's appeal at the time was that its success rate compared favorably with that of physicians, particularly when it came to women's health. Most doctors had not been to medical school, there were no antibiotics, and surgical practices were poor. By comparison the placebo effect (being treated at all, no matter what the treatment was) worked well. Stark argues that the "very elaborate and intensely psychological Christian Science 'treatments' maximize such effects, while having the advantage of not causing further harm."
Sources: en.wikipedia.org
== Differentiation of conditions == Clinical attachment loss (CAL) is a critical parameter in periodontal diagnosis, as it reflects true periodontal tissue destruction. However, increased probing depth does not always indicate attachment loss. Conditions such as pseudopockets and gingival enlargement can mimic periodontal pockets clinically, leading to diagnostic confusion. This part of the article discusses CAL in comparison with pseudopockets and gingival enlargement, highlighting their pathogenesis, clinical features, and diagnostic significance.
== Treatment == There is no cure for McLeod syndrome; the treatment is supportive depending on symptoms. Medication may assist with management of epilepsy, and cardiac and psychiatric features, although patients may respond poorly to treatment for chorea.
=== Activated charcoal === Activated charcoal is a substance that can bind to certain toxins in the digestive tract and prevent their absorption into the bloodstream. The effectiveness of this treatment, as well as how long it is effective after ingestion, are subject to debate. According to one source, activated charcoal is only effective within one hour of poison being ingested, although the source does not regard strychnine specifically. Other sources specific to strychnine state that activated charcoal may be used after one hour of ingestion, depending on dose and type of strychnine-containing product. Therefore, other treatment options are generally favoured over activated charcoal. The use of activated charcoal is considered dangerous in patients with tenuous airways or altered mental states.
In the US, the additive is not for direct consumer sale. Lean finely textured beef can constitute up to 15% of ground beef without additional labeling, and it can be added to other meat products such as beef-based processed meats. USDA disallows the use of spinal cord, organ meat such as cow intestines, bones, and connective tissue such as tendons in LFTB. USDA requires the trimmings used to make LFTB to meet the same microbiological standards as other beef. Because of ammonium hydroxide use in its processing, the lean finely textured beef by BPI is not permitted in Canada. Health Canada stated that: "Ammonia is not permitted in Canada to be used in ground beef or meats during their production" and may not be imported, as the Canadian Food and Drugs Act requires that imported meat products meet the same standards and requirements as domestic meat. Canada does allow Cargill's citric acid-produced Finely Textured Meat (FTM) to be "used in the preparation of ground meat" and "identified as ground meat" under certain conditions. Production of mechanically separated meat via use of bones or bone-in cuts of bovine, ovine and caprine animals are prohibited in the European Union.
=== Cultural impact === Diphenhydramine is deemed to have limited abuse potential in the United States owing to its potentially serious side-effect profile and limited euphoric effects, and is not a controlled substance. Since 2002, the US FDA has required special labeling warning against the use of multiple products that contain diphenhydramine. In some jurisdictions, diphenhydramine is often present in postmortem specimens collected during investigation of sudden infant deaths; the drug may play a role in these events. Diphenhydramine is among prohibited and controlled substances in the Republic of Zambia, and travelers are advised not to bring the drug into the country. Several Americans have been detained by the Zambian Drug Enforcement Commission for possession of Benadryl and other over-the-counter medications containing diphenhydramine.
Sources: en.wikipedia.org
Fire was used by the Lower Paleolithic hominins Homo erectus and Homo ergaster as early as 300,000 to 1.5 million years ago and possibly even earlier by the early Lower Paleolithic (Oldowan) hominin Homo habilis or by robust Australopithecines such as Paranthropus. However, the use of fire only became common in the societies of the following Middle Stone Age and Middle Paleolithic. Use of fire reduced mortality rates and provided protection against predators. Early hominins may have begun to cook their food as early as the Lower Paleolithic (c. 1.9 million years ago) or at the latest in the early Middle Paleolithic (c. 250,000 years ago). Some scientists have hypothesized that hominins began cooking food to defrost frozen meat, which would help ensure their survival in cold regions. Archaeologists cite morphological shifts in cranial anatomy as evidence for emergence of cooking and food processing technologies. These morphological changes include decreases in molar and jaw size, thinner tooth enamel, and decrease in gut volume. During much of the Pleistocene epoch, our ancestors relied on simple food processing techniques such as roasting. The Upper Palaeolithic saw the emergence of boiling, an advance in food processing technology which rendered plant foods more digestible, decreased their toxicity, and maximised their nutritional value. Thermally altered rock (heated stones) are easily identifiable in the archaeological record.
During FY2018, the federal government spent $4.11 trillion, up $127 billion or 3.2% vs. FY2017 spending of $3.99 trillion. Spending increased for all major categories and was mainly driven by higher spending for Social Security, net interest on the debt, and defense. Spending as % GDP fell from 20.7% GDP to 20.3% GDP, equal to the 50-year average. During FY2017, the federal government spent $3.98 trillion, up $128 billion or 3.3% vs. FY2016 spending of $3.85 trillion. Major categories of FY 2017 spending included: Healthcare such as Medicare and Medicaid ($1,077B or 27% of spending), Social Security ($939B or 24%), non-defense discretionary spending used to run federal Departments and Agencies ($610B or 15%), Defense Department ($590B or 15%), and interest ($263B or 7%). Expenditures are classified as "mandatory", with payments required by specific laws to those meeting eligibility criteria (e.g., Social Security and Medicare), or "discretionary", with payment amounts renewed annually as part of the budget process. Around two thirds of federal spending is for "mandatory" programs. CBO projects that mandatory program spending and interest costs will rise relative to GDP over the 2016–2026 period, while defense and other discretionary spending will decline relative to GDP.
=== Medicine === Design based on supramolecular chemistry has inspired the design of functional biomaterials and therapeutics. Supramolecular biomaterials afford a number of modular and generalizable platforms with tunable mechanical, chemical and biological properties. These include systems based on supramolecular assembly of peptides, host–guest macrocycles, high-affinity hydrogen bonding, and metal–ligand interactions. A supramolecular approach has been used extensively to create artificial ion channels for the transport of sodium and potassium ions into and out of cells. Supramolecular interactions influence drug-target binding. In the area of drug delivery, supramolecular chemistry could provide encapsulation and targeted release mechanisms. In addition, supramolecular systems have been designed to disrupt protein–protein interactions that are important to cellular function.
Mycosporine-like amino acids (MAAs) are small secondary metabolites produced by organisms that live in environments with high volumes of sunlight, usually marine environments. The exact number of compounds within this class of natural products is yet to be determined, since they have only relatively recently been discovered and novel molecular species are constantly being discovered; however, to date their number is around 30. They are commonly described as "microbial sunscreens" although their function is believed not to be limited to sun protection. MAAs represent high potential in cosmetics, and biotechnological applications. Indeed, their UV-absorbing properties would allow to create products derived from natural photoprotectors, potentially harmless to the environment and efficient against UV damage.
== Research == Moxidectin is being evaluated as a treatment for scabies. It is established in veterinary medicine to treat a range of parasites, including sarcoptic mange. Its advantage over ivermectin is its longer half-life in humans, thus the potential duration of action.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.